Fact CheckerSign in

NCT03217188CompletedPhase 2

Proton Re-Irradiation for Recurrent Head and Neck Cancer

A Phase II Study of Proton Re-Irradiation for Recurrent Head and Neck Cancer

Source: ClinicalTrials.gov · Last updated 23 Mar 2026

Brief summary (registry, in English)

The purpose of this study is to evaluate the tumor control and the side effects of using proton therapy for head and neck cancer that has come back.

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
87 (actual)
First submitted
11 Jul 2017
Start date
10 Jul 2017
Primary completion date
18 Mar 2026
Lead sponsor
Memorial Sloan Kettering Cancer Center
NCT number
NCT03217188

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 87
  • From 10 Jul 2017 to the primary completion date, 18 Mar 2026
  • 9 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • \<6 months between completion of prior RT and initiation of reirradiation using proton therapy

Other

  • Women who are pregnant or lactating
  • Inability to comply with study and/or follow-up procedures

Who the study is looking for

  • Patient willing and able to provide written informed consent
  • Age ≥18 years at the time of consent
  • Pathologically confirmed diagnosis of a recurrent or a new primary head and neck cancer
  • A history of prior radiation to the head and neck (\>/= 40 Gy, in 2 Gy/fraction equivalent)
  • The recurrent or the second primary tumor is unresectable, the patient elects against surgical resection; patients who underwent surgery who has indications for postoperative radiation therapy is also eligible
  • Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months after treatment Note: Patient with \<6 months of life expectancy will be treated with palliative QUAD shot radiotherapy and those with \> 6 months of life expectancy will be treated with conventionally fractionated full dose re-irradiation approach. Additional other factors determining which patients will be treated with Quad Shot therapy rather than full dose are if the patients have poor performance status, bulky or diffuse disease, significant medical co-morbidities, and significant metastatic disease burden.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (9)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Memorial Sloan Kettering Basking Ridge
Coordinator of this site? Confirm its status
Basking RidgeUnited StatesUnknown status
Memorial Sloan Kettering Commack
Coordinator of this site? Confirm its status
CommackUnited StatesUnknown status
Memorial Sloan Kettering Westchester
Coordinator of this site? Confirm its status
HarrisonUnited StatesUnknown status
Baptist Alliance - McI
Coordinator of this site? Confirm its status
MiamiUnited StatesUnknown status
Memorial Sloan Kettering Monmouth
Coordinator of this site? Confirm its status
MiddletownUnited StatesUnknown status
Memorial Sloan Kettering Bergen
Coordinator of this site? Confirm its status
MontvaleUnited StatesUnknown status
Memorial Sloan-Kettering Cancer Center
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Memorial Sloan Kettering Rockville Centre
Coordinator of this site? Confirm its status
Rockville CentreUnited StatesUnknown status
Memorial Sloan Kettering Nassau
Coordinator of this site? Confirm its status
UniondaleUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.